Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Jan 1995;47(1):312-318
Technology appraisal guidance [TA875]
If you need some outside assistance on your weight loss journey, contact our team to discuss semaglutide injections or read on for more information
In 2025, the company reported a -1.73% YoY (Jan-Dec25) decline in revenue, reflecting portfolio dynamics: Entyvio ($6.14B) continues to anchor growth in inflammatory bowel disease, Takhzyro ($1.44B) shows steady momentum in rare diseases, while Gattex/Revestive ($913.56M) remains a solid contributor in gastrointestinal disorders partially offset by generic pressure and loss of exclusivity in some legacy products
Pioglitazone Actavis EPAR Product Information
134 These observations underscore the complex and context-dependent effects of ERAD in adipose tissue, linking local proteostasis to systemic lipid homeostasis
